Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis

Study of 12 Cases of Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis and Review of the Literature


Lead Sponsor: Hospices Civils de Lyon

Source Hospices Civils de Lyon
Brief Summary

Herpes Simplex Virus encephalitis is the most common infectious encephalitis, with an estimated annual incidence of 1 / 250,000 to 1 / 500,000 in industrialized countries. Despite a widely used antiviral treatment, the prognosis remains poor with a mortality of 5 to 20% and a considerable morbidity rate. One of the contributing factors of bad prognosis is the development of encephalitis mediated by autoantibodies, most often directed against NMDA receptors, in the weeks following viral encephalitis. The description of this pathology is recent, the pathophysiology of this process remains poorly understood, and the management of these patients is not yet codified.

Overall Status Recruiting
Start Date April 1, 2020
Completion Date October 1, 2020
Primary Completion Date June 1, 2020
Study Type Observational
Primary Outcome
Measure Time Frame
Details of clinical, biological, imaging, therapeutic characteristics and patient's evolution. at 6 and 12 months
Enrollment 12

Intervention Type: Other

Intervention Name: Description and analysis

Description: Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.

Arm Group Label: Cohort NMDARE-HSE


Sampling Method: Non-Probability Sample


Inclusion Criteria: - Clinical autoimmune encephalitis with anti-NMDA antibodies and documented by CBA in the CSF - After a herpetic encephalitis documented by a positive viral PCR for HSV in the CSF - Without age limit Exclusion Criteria- No respect of inclusion criteria

Gender: All

Minimum Age: N/A

Maximum Age: N/A

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Jérôme Honnorat Study Director National Reference Center of autoimmune encephalitis
Overall Contact

Last Name: Jérôme Honnorat, PhD

Phone: 04 72 35 78 06

Email: [email protected]

Facility: Status: Contact: Hospice Civils de Lyon JEROME HONNORAT, PhD 04 72 35 78 06 [email protected]
Location Countries


Verification Date

April 2020

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Arm Group

Label: Cohort NMDARE-HSE

Description: Patients developing clinical autoimmune encephalitis with anti-NMDA antibodies after a herpetic encephalitis, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis at the Neurological Hospital of Bron.

Patient Data No
Study Design Info

Observational Model: Cohort

Time Perspective: Retrospective


Clinical Research News